Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer directly owned 76,865 shares in the company, valued at $922,380. The trade was a 8.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Monday, June 29th, Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00.

Candel Therapeutics Trading Up 12.0%

CADL stock traded up $1.45 during mid-day trading on Wednesday, reaching $13.50. The company’s stock had a trading volume of 2,375,183 shares, compared to its average volume of 1,537,261. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -9.57 and a beta of -0.51. Candel Therapeutics, Inc. has a 12 month low of $4.35 and a 12 month high of $13.82. The business’s 50 day moving average price is $9.82 and its 200 day moving average price is $7.50. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). On average, equities research analysts predict that Candel Therapeutics, Inc. will post -1.3 EPS for the current year.

Institutional Investors Weigh In On Candel Therapeutics

Several large investors have recently bought and sold shares of CADL. BNP Paribas Financial Markets raised its holdings in Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after acquiring an additional 7,527 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Candel Therapeutics during the fourth quarter worth $51,000. ProShare Advisors LLC acquired a new position in shares of Candel Therapeutics during the fourth quarter worth $59,000. Finally, Invesco Ltd. purchased a new stake in shares of Candel Therapeutics during the 1st quarter valued at $59,000. Institutional investors own 13.93% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CADL. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Bank of America lifted their price target on shares of Candel Therapeutics from $9.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Candel Therapeutics in a report on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.29.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.